Bone marrow and the control of immunity

Cellular and Molecular Immunology

Volumn 9, Issue 1, 2012, Pages 11-19

  Zhao, Ende ^a,b   Xu, Huanbin ^c   Wang, Lin ^b   Kryczek, Ilona ^a   Wu, Ke ^b   Hu, Yu ^b   Wang, Guobin ^b   Zou, Weiping ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

bone marrow; immunity; memory T cell; regulatory T cell; tumor

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GUANINE NUCLEOTIDE BINDING PROTEIN; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 7; STAT3 PROTEIN; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; VASCULAR CELL ADHESION MOLECULE 1;

B LYMPHOCYTE; BONE MARROW; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELL COMPOSITION; CELL DIFFERENTIATION; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; IMMUNOSTIMULATION; INNATE IMMUNITY; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOID ORGAN; MESENCHYMAL STEM CELL; NATURAL KILLER T CELL; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PLASMA CELL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TH17 CELL; TUMOR IMMUNITY;

ANIMALS; BONE MARROW; BONE MARROW NEOPLASMS; DENDRITIC CELLS; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES; MESENCHYMAL STEM CELLS; NEOPLASM METASTASIS; NEUTROPHILS;

EID: 84855396728     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2011.47     Document Type: Review

References (147)

1. Kopp HG, Avecilla ST, Hooper AT, Rafii S. The bone marrow vascular niche: home of HSC differentiation and mobilization. Physiology (Bethesda) 2005; 20: 349-356. (Pubitemid 41457400)
2. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 2003; 9: 702-712. (Pubitemid 36749219)
3. Tripp RA, Topham DJ, Watson SR, Doherty PC. Bone marrow can function as a lymphoid organ during a primary immune response under conditions of disrupted lymphocyte trafficking. J Immunol 1997; 158: 3716-3720. (Pubitemid 127488726)
4. Dejbakhsh-Jones S, Jerabek L, Weissman IL, Strober S. Extrathymic maturation of alpha beta T cells from hemopoietic stem cells. J Immunol 1995; 155: 3338-3344.
5. Schirrmacher V, Feuerer M, Fournier P, Ahlert T, Umansky V, Beckhove P. T-cell priming in bone marrow: the potential for long-lasting protective anti-tumor immunity. Trends Mol Med 2003; 9: 526-534. (Pubitemid 38017191)
6. Feuerer M, Beckhove P, Mahnke Y, Hommel M, Kyewski B, Hamann A et al. Bone marrow microenvironment facilitating dendritic cell: CD4 T cell interactions and maintenance of CD4 memory. Int J Oncol 2004; 25: 867-876.
7. Feuerer M, Beckhove P, Garbi N, Mahnke Y, Limmer A, Hommel M et al. Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med 2003; 9: 1151-1157. (Pubitemid 37173699)
8. 1 T cells. Immunity 2005; 22: 259-270. (Pubitemid 40255716)
9. Slifka MK, Whitmire JK, Ahmed R. Bone marrow contains virus-specific cytotoxic T lymphocytes. Blood 1997; 90: 2103-2108. (Pubitemid 27377327)
10. Zeng D, Hoffmann P, Lan F, Huie P, Higgins J, Strober S. Unique patterns of surface receptors, cytokine secretion, and immune functions distinguish T cells in the bone marrow from those in the periphery: impact on allogeneic bone marrow transplantation. Blood 2002; 99: 1449-1457. (Pubitemid 34547104)
11. 1 T cells in mouse bone marrow. I. Increased activated/memory phenotype and altered TCR Vbeta repertoire. Eur J Immunol 1999; 29: 1051-1056. (Pubitemid 29119086)
12. 1 regulatory T cells that traffic through cxcl12/cxcr4 signals. Cancer Res 2004; 64: 8451-8455. (Pubitemid 39491786)
13. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767-811. (Pubitemid 30365397)
14. 1 cells. J Immunol 1990; 145: 3209-3215.
15. Higuchi M, Zeng D, Shizuru J, Gworek J, Dejbakhsh-Jones S, Taniguchi M et al. Immune tolerance to combined organ and bone marrow transplants after fractionated lymphoid irradiation involves regulatory NK T cells and clonal deletion. J Immunol 2002; 169: 5564-5570. (Pubitemid 35291655)
16. 1 T cells in the bone marrow: divergence from the thymus. J Immunol 1999; 163: 5338-5345.
17. Fry TJ, Mackall CL. The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol 2005; 174: 6571-6576. (Pubitemid 40705615)
18. 1 T cells. J Exp Med 2001; 194: 1711-1719. (Pubitemid 34028651)
19. 1 cells. J Exp Med 2002; 195: 1523-1532. (Pubitemid 34666066)
20. 1 T cell survival but not for antigen proliferation. Nat Immunol 2000; 1: 54-58.
21. 1 T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res 2007; 67: 7487-7494. (Pubitemid 47206578)
22. Wei S, Kryczek I, Zou W. Regulatory T-cell compartmentalization and trafficking. Blood 2006; 108: 426-431. (Pubitemid 44061338)
23. Avecilla ST, Hattori K, Heissig B, Tejada R, Liao F, Shido K et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med 2004; 10: 64-71. (Pubitemid 38524700)
24. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42-48. (Pubitemid 34059216)
25. Herrmann MM, Gaertner S, Stadelmann C, van den Brandt J, Boscke R, Budach W et al. Tolerance induction by bone marrow transplantation in a multiple sclerosis model. Blood 2005; 106: 1875-1883. (Pubitemid 41208608)
26. Kryczek I, Liu R, Wang G, Wu K, Shu X, Szeliga W et al. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res 2009; 69: 3995-4000.
27. Wilke CM, Wu K, Zhao E, Wang G, Zou W. Prognostic significance of regulatory T cells in tumor. Int J Cancer 2010; 127: 748-758.
28. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-949. (Pubitemid 39273735)
29. 1 regulatory T cells in solid organ transplantation. Curr Opin Organ Transplant 2010; 15: 757-764.
30. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263-274. (Pubitemid 40488632)
31. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295-307.
32. Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2011; 10: 248-256.
33. Prabhala RH, Pelluru D, Fulciniti M, Prabhala HK, Nanjappa P, Song W et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 2010; 115: 5385-5392.
34. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009; 114: 1141-1149.
35. 1 T cell pool IL-1 subverts IL-2-mediated suppression. J Immunol 2007; 179: 1423-1426.
36. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006; 203: 2271-2279. (Pubitemid 44498362)
37. Kryczek I, Wei S, Szeliga W, Vatan L, Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009; 114: 357-359.
38. 1 T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol 2008; 181: 4733-4741.
39. Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 2007; 178: 6730-6733. (Pubitemid 46847396)
40. Noonan K, Marchionni L, Anderson J, Pardoll D, Roodman GD, Borrello I. A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 2010; 116: 3554-3563.
41. Ghannam S, Pene J, Torcy-Moquet G, Jorgensen C, Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 2010; 185: 302-312.
42. Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, Miller SD et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 2009; 57: 1192-1203.
43. Kong QF, Sun B, Wang GY, Zhai DX, Mu LL, Wang DD et al. BM stromal cells ameliorate experimental autoimmune myasthenia gravis by altering the balance of Th cells through the secretion of IDO. Eur J Immunol 2009; 39: 800-809.
44. Kappel LW, Goldberg GL, King CG, Suh DY, Smith OM, Ligh C et al. IL-17 contributes to CD4-mediated graft-versus-host disease. Blood 2009; 113: 945-52.
45. Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, Drobyski WR. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood 2007; 110: 3804-3813. (Pubitemid 350159652)
46. 1 T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol 2009; 145: 64-72.
47. Becker TC, Coley SM, Wherry EJ, Ahmed R. Bone marrow is a preferred site for homeostatic proliferation of memory CD8 T cells. J Immunol 2005; 174: 1269-1273.
48. 1 T cells. Proc Natl Acad Sci USA 2001; 98: 6313-6318. (Pubitemid 32488236)
49. Masopust D, Vezys V, Marzo AL, Lefrancois L. Preferential localization of effector memory cells in nonlymphoid tissue. Science 2001; 291: 2413-2417. (Pubitemid 32231804)
50. Parretta E, Cassese G, Barba P, Santoni A, Guardiola J, Di Rosa F. CD8 cell division maintaining cytotoxic memory occurs predominantly in the bone marrow. J Immunol 2005; 174: 7654-7664. (Pubitemid 40806270)
51. 1 T cells. J Exp Med 2001; 194: 953-966. (Pubitemid 32953264)
52. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 2005; 23: 877-900. (Pubitemid 40563188)
53. 1 cells: new clues to their origin, specificity, and function. J Exp Med 1995; 182: 633-638.
54. Tan JT, Dudl E, LeRoy E, Murray R, Sprent J, Weinberg KI et al. IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc Natl Acad Sci USA 2001; 98: 8732-8737. (Pubitemid 32678096)
55. 1 cells responsible for acute marrow graft rejection are present in thymus-deficient mice. J Immunol 1992; 149: 403-412.
56. Sato K, Ohtsuka K, Hasegawa K, Yamagiwa S, Watanabe H, Asakura H et al. Evidence for extrathymic generation of intermediate T cell receptor cells in the liver revealed in thymectomized, irradiated mice subjected to bone marrow transplantation. J Exp Med 1995; 182: 759-767.
57. 1 NKT cells after hematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 34: 595-602. (Pubitemid 39341539)
58. 1 cells alleviates graft-versus-host disease in a murine model of semiallogeneic bone marrow transplantation: a potential role for NKT lymphocytes. Bone Marrow Transplant 2005; 35: 191-197. (Pubitemid 40185936)
59. Smyth MJ, Crowe NY, Hayakawa Y, Takeda K, Yagita H, Godfrey DI. NKT cells-conductors of tumor immunity? Curr Opin Immunol 2002; 14: 165-171.
60. 1 T-cell subsets in human bone marrow: implications for immunosurveillance of neoplasia. Clin Immunol 2005; 114: 42-51. (Pubitemid 39642789)
61. 1 T cells reciprocally regulate acute graft versus host disease. J Exp Med 1999; 189: 1073-1081. (Pubitemid 29169824)
62. Tokoyoda K, Egawa T, Sugiyama T, Choi BI, Nagasawa T. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 2004; 20: 707-718. (Pubitemid 38757441)
63. Sandel PC, Gendelman M, Kelsoe G, Monroe JG. Definition of a novel cellular constituent of the bone marrow that regulates the response of immature B cells to B cell antigen receptor engagement. J Immunol 2001; 166: 5935-5944. (Pubitemid 32440717)
64. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 1998; 8: 363-372. (Pubitemid 28188896)
65. Manz RA, Thiel A, Radbruch A. Lifetime of plasma cells in the bone marrow. Nature 1997; 388: 133-134. (Pubitemid 27297440)
66. Minges Wols HA, Underhill GH, Kansas GS, Witte PL. The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity. J Immunol 2002; 169: 4213-4221. (Pubitemid 35178192)
67. Hargreaves DC, Hyman PL, Lu TT, Ngo VN, Bidgol A, Suzuki G et al. A coordinated change in chemokine responsiveness guides plasma cell movements. J Exp Med 2001; 194: 45-56. (Pubitemid 32660436)
68. Hauser AE, Debes GF, Arce S, Cassese G, Hamann A, Radbruch A et al. Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response. J Immunol 2002; 169: 1277-1282. (Pubitemid 34809169)
69. Tokoyoda K, Hauser AE, Nakayama T, Radbruch A. Organization of immunological memory by bone marrow stroma. Nat Rev Immunol 2010; 10: 193-200.
70. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 2006; 6: 173-182. (Pubitemid 43290987)
71. Christopher MJ, Link DC. Regulation of neutrophil homeostasis. Curr Opin Hematol 2007; 14: 3-8. (Pubitemid 44885605)
72. Borregaard N. Neutrophils, from marrow to microbes. Immunity 2010; 33: 657-670.
73. Rosmarin AG, Yang Z, Resendes KK. Transcriptional regulation in myelopoiesis: hematopoietic fate choice, myeloid differentiation, and leukemogenesis. Exp Hematol 2005; 33: 131-143. (Pubitemid 40164893)
74. Ray D, Culine S, Tavitain A, Moreau-Gachelin F. The human homologue of the putative proto-oncogene Spi-1: characterization and expression in tumors. Oncogene 1990; 5: 663-668.
75. Nerlov C, Graf T. PU.1 induces myeloid lineage commitment in multipotent hematopoietic progenitors. Genes Dev 1998; 12: 2403-2412. (Pubitemid 28371359)
76. Iwasaki H, Somoza C, Shigematsu H, Duprez EA, Iwasaki-Arai J, Mizuno S et al. Distinctive and indispensable roles of PU.1 in maintenance of hematopoietic stem cells and their differentiation. Blood 2005; 106: 1590-1600. (Pubitemid 41208570)
77. Reddy VA, Iwama A, Iotzova G, Schulz M, Elsasser A, Vangala RK et al. Granulocyte inducer C/EBPalpha inactivates the myeloid master regulator PU.1: possible role in lineage commitment decisions. Blood 2002; 100: 483-490. (Pubitemid 34761110)
78. Dahl R, Walsh JC, Lancki D, Laslo P, Iyer SR, Singh H et al. Regulation of macrophage and neutrophil cell fates by the PU.1:C/EBPalpha ratio and granulocyte colony-stimulating factor. Nat Immunol 2003; 4: 1029-1036. (Pubitemid 37265925)
79. Laslo P, Spooner CJ, Warmflash A, Lancki DW, Lee HJ, Sciammas R et al. Multilineage transcriptional priming and determination of alternate hematopoietic cell fates. Cell 2006; 126: 755-766. (Pubitemid 44233633)
80. Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci USA 1997; 94: 569-574. (Pubitemid 27053674)
81. Karsunky H, Zeng H, Schmidt T, Zevnik B, Kluge R, Schmid KW et al. Inflammatory reactions and severe neutropenia in mice lacking the transcriptional repressor Gfi1. Nat Genet 2002; 30: 295-300.
82. Hock H, Hamblen MJ, Rooke HM, Traver D, Bronson RT, Cameron S et al. Intrinsic requirement for zinc finger transcription factor Gfi-1 in neutrophil differentiation. Immunity 2003; 18: 109-120. (Pubitemid 36120692)
83. Lord BI, Bronchud MH, Owens S, Chang J, Howell A, Souza L et al. The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci USA 1989; 86: 9499-9503. (Pubitemid 20010454)
84. Richards MK, Liu F, Iwasaki H, Akashi K, Link DC. Pivotal role of granulocyte colony-stimulating factor in the development of progenitors in the common myeloid pathway. Blood 2003; 102: 3562-3568. (Pubitemid 37409371)
85. Cartwright GE, Athens JW, Wintrobe MM. The kinetics of granulopoiesis in normal man. Blood 1964; 24: 780-803.
86. Semerad CL, Liu F, Gregory AD, Stumpf K, Link DC. G-CSF is an essential regulator of neutrophil trafficking from the bone marrow to the blood. Immunity 2002; 17: 413-423. (Pubitemid 35223531)
87. Eash KJ, Means JM, White DW, Link DC. CXCR4 is a key regulator of neutrophil release from the bone marrow under basal and stress granulopoiesis conditions. Blood 2009; 113: 4711-4719.
88. Martin C, Burdon PC, Bridger G, Gutierrez-Ramos JC, Williams TJ, Rankin SM. Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. Immunity 2003; 19: 583-593. (Pubitemid 37311439)
89. Semerad CL, Christopher MJ, Liu F, Short B, Simmons PJ, Winkler I et al. G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood 2005; 106: 3020-3027. (Pubitemid 41565894)
90. Christopher MJ, Liu F, Hilton MJ, Long F, Link DC. Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization. Blood 2009; 114: 1331-1339.
91. Rankin SM. The bone marrow: a site of neutrophil clearance. J Leukoc Biol 2010; 88: 241-251.
92. Furze RC, Rankin SM. The role of the bone marrow in neutrophil clearance under homeostatic conditions in the mouse. FASEB J 2008; 22: 3111-3119.
93. Nagase H, Miyamasu M, Yamaguchi M, Imanishi M, Tsuno NH, Matsushima K et al. Cytokine-mediated regulation of CXCR4 expression in human neutrophils. J Leukoc Biol 2002; 71: 711-717.
94. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002; 20: 621-667. (Pubitemid 34293436)
95. Cavanagh LL, Bonasio R, Mazo IB, Halin C, Cheng G, van der Velden AW et al. Activation of bone marrow-resident memory T cells by circulating, antigen-bearing dendritic cells. Nat Immunol 2005; 6: 1029-1037. (Pubitemid 41486188)
96. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004; 22: 745-763. (Pubitemid 38680440)
97. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-174.
98. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004; 4: 941-952. (Pubitemid 39620069)
99. 1 T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004; 172: 989-999. (Pubitemid 38113758)
100. Kusmartsev S, Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 2006; 55: 237-245. (Pubitemid 41683212)
101. Movahedi K, Guilliams M, van den Bossche J, van den Bergh R, Gysemans C, Beschin A et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008; 111: 4233-4244.
102. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008; 181: 5791-5802.
103. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 2007; 13: 721s726s.
104. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001; 166: 678-689. (Pubitemid 32038493)
105. 1 myeloid cells. Cancer Res 2006; 66: 6807-6815. (Pubitemid 44085641)
106. 1 immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006; 66: 1123-1131. (Pubitemid 43165981)
107. Ribechini E, Greifenberg V, Sandwick S, Lutz MB. Subsets, expansion and activation of myeloid-derived suppressor cells. Med Microbiol Immunol 2010; 199: 273-281.
108. Highfill SL, Rodriguez PC, Zhou Q, Goetz CA, Koehn BH, Veenstra R et al. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) viaan arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood 2010; 116: 5738-5747.
109. Caplan AI. Mesenchymal stem cells. J Orthop Res 1991; 9: 641-650.
110. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003; 31: 890-896. (Pubitemid 37211373)
111. Klyushnenkova E, Mosca JD, Zernetkina V, Majumdar MK, Beggs KJ, Simonetti DW et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 2005; 12: 47-57. (Pubitemid 40576763)
112. Majumdar MK, Thiede MA, Haynesworth SE, Bruder SP, Gerson SL. Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. J Hematother Stem Cell Res 2000; 9: 841-848. (Pubitemid 32110282)
113. Cheng L, Hammond H, Ye Z, Zhan X, Dravid G. Human adult marrow cells support prolonged expansion of human embryonic stem cells in culture. Stem Cells 2003; 21: 131-142. (Pubitemid 36331756)
114. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003; 57: 11-20. (Pubitemid 38019084)
115. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838-3843. (Pubitemid 34534559)
116. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101: 3722-3729. (Pubitemid 36857965)
117. Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005; 105: 2821-2827. (Pubitemid 40446275)
118. Plumas J, Chaperot L, Richard MJ, Molens JP, Bensa JC, Favrot MC. Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 2005; 19: 1597-1604. (Pubitemid 43090404)
119. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-1822. (Pubitemid 40223708)
120. Potian JA, Aviv H, Ponzio NM, Harrison JS, Rameshwar P. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol 2003; 171: 3426-3434. (Pubitemid 37254543)
121. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107: 367-372. (Pubitemid 43053565)
122. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105: 4120-4126. (Pubitemid 40656164)
123. 1-derived and monocyte-derived dendritic cells. J Immunol 2006; 177: 2080-2087. (Pubitemid 44200965)
124. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24: 74-85.
125. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008; 111: 1327-1333. (Pubitemid 351213419)
126. Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 1995; 16: 557-564.
127. Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999; 5: 309-313. (Pubitemid 29124367)
128. Bang OY, Lee JS, Lee PH, Lee G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 2005; 57: 874-882. (Pubitemid 40798626)
129. Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004; 94: 92-95. (Pubitemid 38813459)
130. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579-1586. (Pubitemid 351626841)
131. Miller JP, Izon D, DeMuth W, Gerstein R, Bhandoola A, Allman D. The earliest step in B lineage differentiation from common lymphoid progenitors is critically dependent upon interleukin 7. J Exp Med 2002; 196: 705-711. (Pubitemid 35024447)
132. Peschon JJ, Morrissey PJ, Grabstein KH, Ramsdell FJ, Maraskovsky E, Gliniak BC et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med 1994; 180: 1955-1960.
133. Roifman CM, Zhang J, Chitayat D, Sharfe N. A partial deficiency of interleukin-7R alpha is sufficient to abrogate T-cell development and cause severe combined immunodeficiency. Blood 2000; 96: 2803-2807.
134. Schluns KS, Kieper WC, Jameson SC, Lefrancois L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol 2000; 1: 426-432.
135. Becker TC, Wherry EJ, Boone D, Murali-Krishna K, Antia R, Ma A et al. Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J Exp Med 2002; 195: 1541-1548. (Pubitemid 34666068)
136. 1 T cells. J Exp Med 2002; 195: 1533-1539. (Pubitemid 34666067)
137. 1 T cells. Proc Natl Acad Sci USA 2004; 101: 1969-1974. (Pubitemid 38228999)
138. Di Carlo E, Comes A, Orengo AM, Rosso O, Meazza R, Musiani P et al. IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice. J Immunol 2004; 172: 1540-1547. (Pubitemid 38116798)
139. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000; 408: 57-63.
140. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996; 382: 635-638. (Pubitemid 26268957)
141. 1 cells on vascular endothelium under shear flow. J Clin Invest 1999; 104: 1199-1211. (Pubitemid 29536291)
142. 1 cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood 2000; 95: 3289-3296. (Pubitemid 30428455)
143. Lapidot T, Kollet O. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice. Leukemia 2002; 16: 1992-2003. (Pubitemid 35203441)
144. Ma Q, Jones D, Springer TA. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 1999; 10: 463-471. (Pubitemid 29205482)
145. 1 stem/progenitor cells to bone marrow. Blood 2004; 103: 2981-2989. (Pubitemid 38451670)
146. Koni PA, Joshi SK, Temann UA, Olson D, Burkly L, Flavell RA. Conditional
147. Frenette PS, Subbarao S, Mazo IB, von Andrian UH, Wagner DD. Endothelial selectins and vascular cell adhesion molecule-1 promote hematopoietic progenitor homing to bone marrow. Proc Natl Acad Sci USA 1998; 95: 14423-14428. (Pubitemid 28549383)